Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Sickle Cell
•
Pediatric Hematology
•
Benign Hematology
When would you consider upfront eculizumab for sickle cell hyperhemolysis?
How long after eculizumab infusion would you wait before giving blood transfusions?
Related Questions
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
Is there any indication for hydroxyurea in patients with sickle cell trait?
What subset of sickle cell disease patients are you offering sickle cell disease gene therapy?
Would you consider continuing or re-trialing hydroxyurea for sickle cell patients after development of a leg ulcer?
Do you screen children with sickle cell disease for silent cerebral infarcts?
Is there any indication for monitoring for renal medullary carcinoma in patients with sickle cell trait?
What additional testing is recommended with heterozygous HFE C282Y mutation whose ferritin is elevated and transferrin saturation percentage is at baseline?
What would you recommend for long term management of extensive dural venous sinus thrombosis (CVST) in young females when the only provoking risk factor is combined OCP?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
Would you anticoagulate a patient with splenic infarctions in the setting of CMV viremia?